1,717 results on '"Reiberger, Thomas"'
Search Results
2. FXR-FGF19 signaling in the gut–liver axis is dysregulated in patients with cirrhosis and correlates with impaired intestinal defence
3. ELIMINATE: a PCR record-based macroelimination project for systematic recall of HCV-RNA-positive persons in Austria
4. Clinical course of congestive hepatopathy pre/post heart transplantation
5. Rapid improvement of hepatic steatosis and liver stiffness after metabolic/bariatric surgery: a prospective study
6. Use of the CytoSorb adsorber in patients with acute-on-chronic liver failure
7. Management of varices but not anticoagulation is associated with improved outcome in patients with HCC and macrovascular tumour invasion
8. Von Willebrand factor processing in patients with advanced chronic liver disease and its relation to portal hypertension and clinical outcome
9. Endoscopic band ligation is safe despite low platelet count and high INR
10. EASL position paper on clinical follow-up after HCV cure
11. WFUMB Guidelines/Guidance on Liver Multiparametric Ultrasound. Part 2: Guidance on Liver Fat Quantification
12. WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography
13. Validation of Baveno VII criteria and other non-invasive diagnostic algorithms for clinically significant portal hypertension in hepatitis delta
14. Post-treatment LSM rather than change during treatment predicts decompensation in patients with cACLD after HCV cure
15. Using liver stiffness to predict and monitor the risk of decompensation and mortality in patients with alcohol-related liver disease
16. Bacterial translocation occurs early in cirrhosis and triggers a selective inflammatory response
17. Prevalence and dynamics of NAFLD-associated fibrosis in people living with HIV in Vienna from first presentation to last follow-up
18. Prognostic performance of non-invasive tests for portal hypertension is comparable to that of hepatic venous pressure gradient
19. Gas6 in chronic liver disease—a novel blood-based biomarker for liver fibrosis
20. The systemic and hepatic alternative renin–angiotensin system is activated in liver cirrhosis, linked to endothelial dysfunction and inflammation
21. The rationale and study design of two phase II trials examining the effects of BI 685,509, a soluble guanylyl cyclase activator, on clinically significant portal hypertension in patients with compensated cirrhosis
22. Portal Hypertension in ALD
23. Austrian consensus on the diagnosis and management of portal hypertension in advanced chronic liver disease (Billroth IV)
24. Diagnostik- und Therapieleitfaden 2023 für PBC in Österreich: Primär biliäre Cholangitis frühzeitig erkennen und risikostratifiziert behandeln
25. Transcriptomic signatures of progressive and regressive liver fibrosis and portal hypertension
26. Evolution of spontaneous portosystemic shunts over time and following aetiological intervention in patients with cirrhosis
27. Inhibition of the renal apical sodium dependent bile acid transporter prevents cholemic nephropathy in mice with obstructive cholestasis
28. Inflammasomes in chronic liver disease: Hepatic injury, fibrosis progression and systemic inflammation
29. Diagnostic and prognostic performance of the LiverRisk score in tertiary care
30. Hepatic venous pressure gradient predicts risk of hepatic decompensation and liver-related mortality in patients with MASLD
31. Lower free triiodothyronine (fT3) levels in cirrhosis are linked to systemic inflammation, higher risk of acute-on-chronic liver failure, and mortality
32. Platelet adhesion assessed by PFA-100 is not linked to progression of ACLD
33. Predicting survival in patients with ‘non-high-risk’ acute variceal bleeding receiving β-blockers+ligation to prevent re-bleeding
34. Low mortality despite temporary liver dysfunction in severe courses of acute hepatitis E
35. Imaging features facilitate diagnosis of porto-sinusoidal vascular disorder
36. Development and validation of the AMMON-OHE model to predict risk of overt hepatic encephalopathy occurrence in outpatients with cirrhosis
37. Dynamics in Liver Stiffness Measurements Predict Outcomes in Advanced Chronic Liver Disease
38. When Is a Critically Ill Cirrhotic Patient Too Sick to Transplant? Development of Consensus Criteria by a Multidisciplinary Panel of 35 International Experts.
39. Accuracy of spleen stiffness measurement for the diagnosis of clinically significant portal hypertension in patients with compensated advanced chronic liver disease: a systematic review and individual patient data meta-analysis
40. TIPS prevents further decompensation and improves survival in patients with cirrhosis and portal hypertension in an individual patient data meta-analysis
41. The impact of transmembrane 6 superfamily 2 (TM6SF2) rs58542926 on liver-related events in patients with advanced chronic liver disease
42. An impaired pituitary–adrenal signalling axis in stable cirrhosis is linked to worse prognosis
43. Long-term follow-up of patients discontinuing bulevirtide treatment upon long-term HDV-RNA suppression
44. Alcohol Abstinence Improves Prognosis Across All Stages of Portal Hypertension in Alcohol-Related Cirrhosis
45. Carvedilol Achieves Higher Hemodynamic Response and Lower Rebleeding Rates Than Propranolol in Secondary Prophylaxis
46. The Sequential Application of Baveno VII Criteria and VITRO Score Improves Diagnosis of Clinically Significant Portal Hypertension
47. Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: The IMPORTAL competing-risk meta-analysis
48. The impact of COVID-19 on liver transplantation programs in Austria
49. Covered Transjugular Intrahepatic Portosystemic Shunt Improves Hypersplenism-Associated Cytopenia in Cirrhosis
50. Hypoalbuminemia affects the spatio-temporal tissue distribution of ochratoxin A in liver and kidneys: consequences for organ toxicity
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.